Clinical Trials Logo

Clinical Trial Summary

The study population is advanced gastric, gastroesophageal, and esophageal adenocarcinoma participants who have failed upfront standard of care chemotherapy. The goal is to demonstrate that Rucaparib plus Ramucirumab with or without Nivolumab has a higher response rate than what has been reported for Ramucirumab in previously treated patients. Trial will be a phase 1/2 trial. The Phase 1 portion will determine the recommended Phase 2 treatment dose for the combination of Rucaparib plus Ramucirumab and Nivolumab and enroll approximately 6-9 participants. The Phase 2 portion of the study will involve 52 participants allocated between two treatment groups comparing Rucaparib plus Ramucirumab with or without Nivolumab. The participants will be selected based on the results of a screening HRD gene panel.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03995017
Study type Interventional
Source University of Kansas Medical Center
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date January 9, 2020
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT05069766 - Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences N/A
Completed NCT04669951 - Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer N/A